Harbour BioMed (HKG: 2142), a biotechnology company with operations in Suzhou, China, Cambridge in the US, and the Netherlands, has announced an antibody drug conjugate (ADC) discovery cooperation agreement with South Korea-based ADC specialist Boostimmune, Inc. The financial details of the agreement have not been disclosed.
As per the terms of the agreement, Harbour BioMed will provide Boostimune access to its dual, double light chain (H2L2) Harbour Mice platform. This technology will be utilized to develop ADC therapies targeting novel cancer antigens.- Flcube.com
